BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 29469670)

  • 1. Role of miRNAs in treatment response and toxicity of childhood acute lymphoblastic leukemia.
    Umerez M; Garcia-Obregon S; Martin-Guerrero I; Astigarraga I; Gutierrez-Camino A; Garcia-Orad A
    Pharmacogenomics; 2018 Mar; 19(4):361-373. PubMed ID: 29469670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MiR-125b, miR-100 and miR-99a co-regulate vincristine resistance in childhood acute lymphoblastic leukemia.
    Akbari Moqadam F; Lange-Turenhout EA; Ariës IM; Pieters R; den Boer ML
    Leuk Res; 2013 Oct; 37(10):1315-21. PubMed ID: 23915977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The miR-1206 microRNA variant is associated with methotrexate-induced oral mucositis in pediatric acute lymphoblastic leukemia.
    Gutierrez-Camino A; Oosterom N; den Hoed MAH; Lopez-Lopez E; Martin-Guerrero I; Pluijm SMF; Pieters R; de Jonge R; Tissing WJE; Heil SG; García-Orad A; van den Heuvel-Eibrink MM
    Pharmacogenet Genomics; 2017 Aug; 27(8):303-306. PubMed ID: 28628559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacoepigenetics in childhood acute lymphoblastic leukemia: involvement of miRNA polymorphisms in hepatotoxicity.
    Gutierrez-Camino A; Umerez M; Santos B; Martin-Guerrero I; García de Andoin N; Sastre A; Navajas A; Astigarraga I; Garcia-Orad A
    Epigenomics; 2018 Apr; 10(4):409-417. PubMed ID: 29569486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of miRNA polymorphism in mucositis development in childhood acute lymphoblastic leukemia treatment.
    Gutierrez-Camino Á; Umerez M; Lopez-Lopez E; Santos-Zorrozua B; Martin-Guerrero I; de Andoin NG; Ana S; Navajas A; Astigarraga I; Garcia-Orad A
    Pharmacogenomics; 2018 Dec; 19(18):1403-1412. PubMed ID: 30479191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia.
    Schotte D; De Menezes RX; Akbari Moqadam F; Khankahdani LM; Lange-Turenhout E; Chen C; Pieters R; Den Boer ML
    Haematologica; 2011 May; 96(5):703-11. PubMed ID: 21242186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics of microRNAs and microRNAs biogenesis machinery in pediatric acute lymphoblastic leukemia.
    López-López E; Gutiérrez-Camino Á; Piñán MÁ; Sánchez-Toledo J; Uriz JJ; Ballesteros J; García-Miguel P; Navajas A; García-Orad Á
    PLoS One; 2014; 9(3):e91261. PubMed ID: 24614921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noncoding RNA-related polymorphisms in pediatric acute lymphoblastic leukemia susceptibility.
    Gutierrez-Camino A; Lopez-Lopez E; Martin-Guerrero I; Piñan MA; Garcia-Miguel P; Sanchez-Toledo J; Carbone Bañeres A; Uriz J; Navajas A; Garcia-Orad A
    Pediatr Res; 2014 Jun; 75(6):767-73. PubMed ID: 24618566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrative computational in-depth analysis of dysregulated miRNA-mRNA interactions in drug-resistant pediatric acute lymphoblastic leukemia cells: an attempt to obtain new potential gene-miRNA pathways involved in response to treatment.
    Mesrian Tanha H; Mojtabavi Naeini M; Rahgozar S; Moafi A; Honardoost MA
    Tumour Biol; 2016 Jun; 37(6):7861-72. PubMed ID: 26700663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of certain leukemia/lymphoma related microRNAs and its correlation with prognosis in childhood acute lymphoblastic leukemia.
    Nemes K; Csóka M; Nagy N; Márk Á; Váradi Z; Dankó T; Kovács G; Kopper L; Sebestyén A
    Pathol Oncol Res; 2015 Jul; 21(3):597-604. PubMed ID: 25388103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia.
    Piatopoulou D; Avgeris M; Drakaki I; Marmarinos A; Xagorari M; Baka M; Pourtsidis A; Kossiva L; Gourgiotis D; Scorilas A
    Ann Hematol; 2018 Jul; 97(7):1169-1182. PubMed ID: 29556721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-326 and microRNA-200c: Two novel biomarkers for diagnosis and prognosis of pediatric acute lymphoblastic leukemia.
    Ghodousi ES; Rahgozar S
    J Cell Biochem; 2018 Jul; 119(7):6024-6032. PubMed ID: 29630744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics of acute lymphoblastic leukemia treatment response.
    Cunningham L; Aplenc R
    Expert Opin Pharmacother; 2007 Oct; 8(15):2519-31. PubMed ID: 17931087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous changes in expression levels of BAALC and miR-326: a novel prognostic biomarker for childhood ALL.
    Ghodousi ES; Aberuyi N; Rahgozar S
    Jpn J Clin Oncol; 2020 Jun; 50(6):671-678. PubMed ID: 32129446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mir-pharmacogenetics of Vincristine and peripheral neurotoxicity in childhood B-cell acute lymphoblastic leukemia.
    Gutierrez-Camino Á; Umerez M; Martin-Guerrero I; García de Andoin N; Santos B; Sastre A; Echebarria-Barona A; Astigarraga I; Navajas A; Garcia-Orad A
    Pharmacogenomics J; 2018 Dec; 18(6):704-712. PubMed ID: 29282364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-125b predicts childhood acute lymphoblastic leukaemia poor response to BFM chemotherapy treatment.
    Piatopoulou D; Avgeris M; Marmarinos A; Xagorari M; Baka M; Doganis D; Kossiva L; Scorilas A; Gourgiotis D
    Br J Cancer; 2017 Sep; 117(6):801-812. PubMed ID: 28787435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miRNA deregulation in childhood acute lymphoblastic leukemia: a systematic review.
    Gutierrez-Camino A; Garcia-Obregon S; Lopez-Lopez E; Astigarraga I; Garcia-Orad A
    Epigenomics; 2020 Jan; 12(1):69-80. PubMed ID: 31833405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polygenic Pharmacogenomic Markers as Predictors of Toxicity Phenotypes in the Treatment of Acute Lymphoblastic Leukemia: A Single-Center Study.
    Larkin T; Kashif R; Elsayed AH; Greer B; Mangrola K; Rafiee R; Nguyen N; Shastri V; Horn B; Lamba JK
    JCO Precis Oncol; 2023 Mar; 7():e2200580. PubMed ID: 36952646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia.
    Davidsen ML; Dalhoff K; Schmiegelow K
    J Pediatr Hematol Oncol; 2008 Nov; 30(11):831-49. PubMed ID: 18989161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics of childhood acute lymphoblastic leukemia.
    Lopez-Lopez E; Gutierrez-Camino A; Bilbao-Aldaiturriaga N; Pombar-Gomez M; Martin-Guerrero I; Garcia-Orad A
    Pharmacogenomics; 2014 Jul; 15(10):1383-98. PubMed ID: 25155938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.